Inhibikase Therapeutics (IKT) Institutional Ownership $3.20 +0.04 (+1.27%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Institutional Ownership Changes (13F Filings) for Inhibikase Therapeutics (NYSE:IKT)CurrentInstitutional OwnershipPercentage3.81%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$713.39KNumber ofInstitutional Sellers(last 12 months)0 Get IKT Insider Trade Alerts Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IKT Institutional Buying and Selling by Quarter Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Inhibikase Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2024 Armistice Capital LLC589,575$713K0.0%N/A8.170% 11/15/2023 Armistice Capital LLC186,046$259K0.0%-62.5%3.477% 9/21/2023 Barclays PLC11,455$41K0.0%N/A0.214% 8/8/2023 Hamilton Lane Advisors LLC13,802$50K0.0%-83.3%0.266% 5/2/2023 Hamilton Lane Advisors LLC82,817$54K0.0%N/A0.286% 2/10/2023 Blair William & Co. IL229,000$114K0.0%+27.9%0.817% Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/12/2022 Koshinski Asset Management Inc.65,377$49K0.0%N/A0.259% 5/6/2022 Retirement Planning Co of New England Inc.116,402$172K0.1%-21.0%0.461% 5/5/2022Lynwood Capital Management Inc.120,000$178K0.2%-52.9%0.476% 5/4/2022 Hamilton Lane Advisors LLC165,635$245K0.1%N/A0.657% 5/3/2022 Redmond Asset Management LLC122,682$182K0.1%N/A0.486% 2/14/2022 Murchinson Ltd.220,947$327K0.0%-31.2%0.878% 2/8/2022 Retirement Planning Co of New England Inc.147,331$216K0.1%N/A0.586% 2/3/2022ACT Capital Management LLC1,076,500$1.58M1.1%+6.6%4.279% 11/16/2021ACT Capital L.L.C.1,010,000$1.92M1.0%+15.4%4.019% 11/16/2021 Warberg Asset Management LLC26,000$49K0.0%-71.1%0.103% 11/9/2021BlackRock Inc.50,741$96K0.0%+273.9%0.202% 8/17/2021Zeke Capital Advisors LLC93,800$263K0.0%+398.9%0.926% 8/16/2021 Antara Capital LP250,000$700K0.0%N/A2.467% 8/16/2021 Warberg Asset Management LLC90,000$252K0.0%N/A0.888% 8/16/2021 Sabby Management LLC421,200$1.18M0.2%N/A4.157% 8/13/2021 Altium Capital Management LP109,749$307K0.1%N/A1.083% 8/13/2021 Murchinson Ltd.320,947$899K0.3%N/A3.167% 8/13/2021 Vanguard Group Inc.470,615$1.32M0.0%N/A4.644% 8/13/2021 FMR LLC433,300$1.21M0.0%+333.3%4.276% 8/12/2021 Kepos Capital LP700,000$1.96M0.1%N/A6.908% 5/21/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/18/2021 Millennium Management LLC11,224$67K0.0%N/A0.112% 5/18/2021 Citadel Advisors LLC17,857$107K0.0%N/A0.178% 5/17/2021 HRT Financial LP11,614$69K0.0%N/A0.115% (Data available from 1/1/2016 forward) IKT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IKT shares? During the previous two years, the following institutional investors and hedge funds held shares of Inhibikase Therapeutics shares: Armistice Capital LLC ($713K), Blair William & Co. IL ($114K), and Hamilton Lane Advisors LLC ($50K), Barclays PLC ($41K).Learn more on IKT's institutional investors. What percentage of Inhibikase Therapeutics stock is owned by institutional investors? 3.81% of Inhibikase Therapeutics stock is owned by institutional investors. Learn more on IKT's institutional investor holdings. Which institutional investors have been buying Inhibikase Therapeutics stock? The following institutional investors have purchased Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($589.58K), Hamilton Lane Advisors LLC ($82.82K), Blair William & Co. IL ($50K), and Barclays PLC ($11.46K). How much institutional buying is happening at Inhibikase Therapeutics? Institutional investors have bought a total of 733,847 shares in the last 24 months. This purchase volume represents approximately $1.44M in transactions. Which Inhibikase Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Inhibikase Therapeutics stock in the last 24 months: Armistice Capital LLC ($310.50K), and Hamilton Lane Advisors LLC ($69.02K). How much institutional selling is happening at Inhibikase Therapeutics? Institutional investors have sold a total of 379,516 shares in the last 24 months. This volume of shares sold represents approximately $1.93M in transactions. Related Companies ADPT Major Shareholders PSTX Major Shareholders IMTX Major Shareholders LENZ Major Shareholders REPL Major Shareholders RLAY Major Shareholders AVXL Major Shareholders AUTL Major Shareholders CGEM Major Shareholders TECX Major Shareholders This page (NYSE:IKT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts